JBCHEPHARM - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

Swing Trade Rating: 4.1

💊 JBCHEPHARM shows strong fundamentals and neutral-to-bullish technicals. Entry near ₹1,680–₹1,690 is optimal. If already held, consider exiting near ₹1,740–₹1,770.

📈 Positive

• ROCE 25.9% and ROE 20.2% — excellent capital efficiency
• EPS ₹43.5 and P/E 39.2 — premium valuation supported by earnings
• MACD 2.71 and RSI 51.9 — neutral momentum with bullish crossover
• Trading near DMA 50 (₹1,694) and DMA 200 (₹1,697) — consolidation zone
• Debt-to-equity 0.00 — zero debt, strong balance sheet
• DII holding increased by 3.21% — strong domestic investor confidence

⚠️ Limitation

• P/E 39.2 vs industry PE 33.1 — slightly overvalued
• PEG ratio 1.65 — moderate valuation relative to growth
• FII holding declined by 2.46% — reduced foreign interest
• Dividend yield 0.91% — modest income support

🚫 Company Negative News

• Stock down ~13% from 52-week high of ₹1,952
• FII outflows may cap near-term upside

✅ Company Positive News

• Strong Q2 performance with PAT growth from ₹150 Cr. to ₹198 Cr.
• Positive sentiment around branded generics and export expansion
• Analysts expect breakout above ₹1,750 if volume sustains

🏭 Industry

• Pharma sector benefits from global demand, regulatory tailwinds, and domestic healthcare growth
• JBCHEPHARM trades slightly above industry PE (33.1) — reflects premium for quality and growth

🧾 Conclusion

• JBCHEPHARM is a technically consolidating and fundamentally strong swing candidate
• Best entry: ₹1,680–₹1,690 near DMA support and RSI base
• If already held, exit near ₹1,740–₹1,770 — resistance zone before 52-week high
• Watch for RSI >55 and MACD continuation for breakout confirmation

I can also compare JBCHEPHARM with peers like IPCA or ALKEM to help you spot stronger swing setups.